Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.74 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12670723 | 0.88 | TSHR (0.57) | TSHRNPC1RAB9AMEN1KMT2A | |
| SCHEMBL12670667 | 0.88 | TSHR (0.57) | TSHRNPC1RAB9AMEN1KMT2A | |
| SCHEMBL12670645 | 0.86 | TSHR (0.65) | TSHRNPC1RAB9ANPSR1MEN1 | |
| SCHEMBL12670712 | 0.85 | NPC1 (0.74) | TSHRNPC1RAB9AMEN1KMT2A | |
| SCHEMBL12670716 | 0.84 | LMNA (0.61) | TSHRNPC1RAB9AHSD17B10 | |
| SCHEMBL12670664 | 0.84 | TSHR (0.51) | TSHRNPSR1MEN1KMT2AALDH1A1 | |
| SCHEMBL12670722 | 0.84 | TSHR (0.51) | TSHRNPC1RAB9ANPSR1 | |
| SCHEMBL12670721 | 0.84 | TSHR (0.51) | TSHRNPC1RAB9ANPSR1ALDH1A1 | |
| SCHEMBL12670719 | 0.84 | TSHR (0.51) | TSHRNPSR1MEN1KMT2AALDH1A1 | |
| SCHEMBL12670660 | 0.82 | MEN1 (0.58) | TSHRNPC1RAB9ANPSR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7947707-B2 | Nitrogenated heterocyclic compound and pharmaceutical composition comprising the same | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2011-05-24 | — | — | US | disclosed |
| US-7947707-B2 | Nitrogenated heterocyclic compound and pharmaceutical composition comprising the same | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2011-05-24 | — | — | US | disclosed |
| US-20090306396-A1 | NITROGENATED HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2009-12-10 | — | — | US | disclosed |
| US-20090306396-A1 | NITROGENATED HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306396-A1 | NITROGENATED HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | XDH, CBR3, CBR1 | TSHR 1257/4885NPC1 851/4885RAB9A 4018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.